guest ::
| Home > Publications database > Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. > print |
| Home > Publications database > Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. > print |
| 001 | 143705 | ||
| 005 | 20240229112605.0 | ||
| 024 | 7 | _ | |a 10.1038/s41573-019-0016-5 |2 doi |
| 024 | 7 | _ | |a pmid:30760888 |2 pmid |
| 024 | 7 | _ | |a 1474-1776 |2 ISSN |
| 024 | 7 | _ | |a 1474-1784 |2 ISSN |
| 024 | 7 | _ | |a altmetric:55401339 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2019-01278 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Platten, Michael |0 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5 |b 0 |e First author |u dkfz |
| 245 | _ | _ | |a Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. |
| 260 | _ | _ | |a London |c 2019 |b Nature Publ. Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1652167290_7791 |2 PUB:(DE-HGF) |x Review Article |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a L-Tryptophan (Trp) metabolism through the kynurenine pathway (KP) is involved in the regulation of immunity, neuronal function and intestinal homeostasis. Imbalances in Trp metabolism in disorders ranging from cancer to neurodegenerative disease have stimulated interest in therapeutically targeting the KP, particularly the main rate-limiting enzymes indoleamine-2,3-dioxygenase 1 (IDO1), IDO2 and tryptophan-2,3-dioxygenase (TDO) as well as kynurenine monooxygenase (KMO). However, although small-molecule IDO1 inhibitors showed promise in early-stage cancer immunotherapy clinical trials, a phase III trial was negative. This Review summarizes the physiological and pathophysiological roles of Trp metabolism, highlighting the vast opportunities and challenges for drug development in multiple diseases. |
| 536 | _ | _ | |a 312 - Functional and structural genomics (POF3-312) |0 G:(DE-HGF)POF3-312 |c POF3-312 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Nollen, Ellen A A |b 1 |
| 700 | 1 | _ | |a Röhrig, Ute F |0 0000-0002-4676-4087 |b 2 |
| 700 | 1 | _ | |a Fallarino, Francesca |0 0000-0002-8501-2136 |b 3 |
| 700 | 1 | _ | |a Opitz, Christiane |0 P:(DE-He78)14aa02d2ca0515d0c53f1d6678e3ca34 |b 4 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.1038/s41573-019-0016-5 |g Vol. 18, no. 5, p. 379 - 401 |0 PERI:(DE-600)2061062-2 |n 5 |p 379 - 401 |t Nature reviews / Drug discovery Drug discovery [...] |v 18 |y 2019 |x 1474-1784 |
| 856 | 4 | _ | |y OpenAccess |u https://inrepo02.dkfz.de/record/143705/files/Platt_Tryptophan_Neu.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://inrepo02.dkfz.de/record/143705/files/Platt_Tryptophan_Neu.pdf?subformat=pdfa |
| 909 | C | O | |o oai:inrepo02.dkfz.de:143705 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)5ef8651b0f857b9c640aa5b1498c43b5 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)14aa02d2ca0515d0c53f1d6678e3ca34 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-312 |3 G:(DE-HGF)POF3 |2 G:(DE-HGF)POF3-300 |4 G:(DE-HGF)POF |v Functional and structural genomics |x 0 |
| 914 | 1 | _ | |y 2019 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NAT REV DRUG DISCOV : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1120 |2 StatID |b BIOSIS Reviews Reports And Meetings |
| 915 | _ | _ | |a IF >= 50 |0 StatID:(DE-HGF)9950 |2 StatID |b NAT REV DRUG DISCOV : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 920 | 1 | _ | |0 I:(DE-He78)D170-20160331 |k D170 |l Neuroimmunologie und Hirntumorimmunologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B350-20160331 |k B350 |l Metabolischer Crosstalk bei Krebserkrankungen |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)L101-20160331 |k L101 |l DKTK Heidelberg |x 2 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-He78)D170-20160331 |
| 980 | _ | _ | |a I:(DE-He78)B350-20160331 |
| 980 | _ | _ | |a I:(DE-He78)L101-20160331 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|